Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

13-11-2019 | Rheumatoid arthritis | Video | Article

Researcher comment: The NORD-STAR trial

print
PRINT
insite
SEARCH

Merete Hetland discusses the NORD-STAR trial findings comparing remission rates after active conventional versus biologic treatment in patients with early rheumatoid arthritis (3:52).  

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Transcript

Back to the ACR/ARP 2019 conference hub

print
PRINT

Related content

13-11-2019 | Rheumatoid arthritis | ACR/ARP 2019 | News

Methotrexate plus glucocorticoids compare favorably with biologics in early RA

31-01-2019 | Rheumatoid arthritis | Highlight | News

Effectiveness of tocilizumab, rituximab over other biologics demonstrated

10-01-2019 | Rheumatoid arthritis | News

Biologic combination therapy for RA may increase risk for side effects

05-11-2019 | Rheumatoid arthritis | Feature | Article

​​​​​​​Treatment tapering in RA: A 2019 update
Why, when, and how should treatment be tapered in people with rheumatoid arthritis?
Image Credits